Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · As of May 2026 — confirm current pricing directly with the pharmacy or manufacturer.
Key Takeaways
- Brand Wegovy list price: approximately $1,349/month at U.S. retail in May 2026
- NovoCare Pharmacy direct-pay program: approximately $499/month for cash-pay patients, shipped manufacturer-direct
- Novo Nordisk Patient Assistance Program: $0 for qualifying uninsured low-income patients
- Compounded semaglutide via 503A pharmacies: $199 to $399/month, not FDA-approved or interchangeable with Wegovy
- Wegovy is the obesity-indicated semaglutide; cash-pay options here differ structurally from Ozempic's
Direct answer
Cash-pay Wegovy in May 2026 has multiple price tiers. Retail list is approximately $1,349 per month. Novo Nordisk's NovoCare Pharmacy direct-pay program offers Wegovy at approximately $499 per month for cash patients, well below retail. The Novo Nordisk Patient Assistance Program brings cost to $0 for qualifying low-income uninsured patients. Compounded semaglutide via 503A pharmacies typically runs $199 to $399 monthly outside the brand channel. Confirm current pricing directly with the pharmacy or manufacturer.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The brand Wegovy retail price right now
- NovoCare Pharmacy: the manufacturer's cash-pay channel
- The Wegovy Savings Card and its uninsured tier
- Novo Nordisk Patient Assistance Program eligibility
- Compounded semaglutide for cash-pay weight management
- Wegovy without insurance vs. Zepbound without insurance
- International Wegovy considerations
- Annual cost projections across paths
- The decision framework
- What we see on the FormBlends platform
- FAQ
- Sources
The brand Wegovy retail price right now
Wegovy's wholesale acquisition cost is set near $1,349 monthly by Novo Nordisk. Cash retail at U.S. pharmacies tracks closely; real quotes in May 2026 cluster between $1,300 and $1,420 depending on the pharmacy and region. Wegovy is the highest-priced brand in the GLP-1 weight-management category at list. Confirm current pricing directly with the pharmacy or manufacturer.
A monthly supply is four single-use autoinjector pens covering one weekly injection each. Dose strengths are 0.25, 0.5, 1, 1.7, and 2.4 mg. Cash pricing is roughly uniform across dose strengths.
NovoCare Pharmacy: the manufacturer's cash-pay channel
In 2025, Novo Nordisk launched a direct-pay program through NovoCare Pharmacy offering Wegovy to cash-paying patients at a substantially reduced price, originally around $499 per month for some doses. The program was Novo Nordisk's response to Lilly Direct's competing Zepbound vial program.
Key features as of May 2026:
- Direct shipment from NovoCare Pharmacy to the patient's address
- Original pen format (not vials)
- Prescription required, written specifically for the NovoCare direct-pay channel
- Cash payment at the time of order; insurance is not billed
- Pricing has been adjusted by Novo Nordisk since launch; verify current rate at NovoCare.com
The program's pricing has been more variable than Lilly Direct's. Patients should check current rates at the time of ordering rather than assuming a static price.
The Wegovy Savings Card and its uninsured tier
The standard Wegovy Savings Card on NovoCare.com primarily serves commercially insured patients, with copays as low as $0 to $25 per fill for eligible patients. The card includes a separate uninsured-tier offer that has historically capped patient cost at a higher level than the commercial-insurance tier but below retail.
For uninsured patients comparing options, the NovoCare direct-pay program at $499 is typically a cleaner pathway than the savings card uninsured tier. Patients should run both numbers at the time of fill.
Patients on Medicare, Medicaid, TRICARE, or VA are not eligible for the savings card under any tier.
Novo Nordisk Patient Assistance Program eligibility
The Novo Nordisk PAP can provide Wegovy at no cost to qualifying patients:
| Requirement | Detail |
|---|---|
| Residency | U.S. citizen or legal resident |
| Income | At or below 400% of the federal poverty level |
| Insurance status | Uninsured, or insured without coverage for Wegovy |
| Diagnosis | BMI 30+ or 27+ with weight-related comorbidity (FDA Wegovy indication) |
| Documentation | Tax return or pay stubs, prescriber attestation |
| Cost | $0 if approved |
| Approval timeline | Three to six weeks |
Approval is typically for 12 months, then must be renewed with updated documentation.
Compounded semaglutide for cash-pay weight management
Compounded semaglutide from a 503A state-licensed compounding pharmacy is the most common cash-pay alternative to brand Wegovy. Pricing typically falls between $199 and $399 monthly when accessed through reputable telehealth platforms.
Compounded semaglutide is not FDA-approved. It is prepared in response to individual prescriptions and is not interchangeable with brand Wegovy. The FDA has periodically restricted compounding of semaglutide based on the shortage list status, and the regulatory environment has shifted multiple times since 2023.
Patients considering compounded semaglutide should:
- Confirm the pharmacy is 503A (not 503B unless explained) and licensed in the state of shipment
- Verify the prescriber is licensed and reviewing the case appropriately
- Understand that compounded products are not equivalent to FDA-approved brand drugs
- Be aware that additives (B12, lipotropics, etc.) included by some compounders are not supported by efficacy data
FormBlends partners with 503A pharmacies for transparent compounded semaglutide programs.
Wegovy without insurance vs. Zepbound without insurance
The structural comparison matters because both are obesity-indicated GLP-1 receptor agonists with overlapping use cases:
| Path | Wegovy approximate cost | Zepbound approximate cost |
|---|---|---|
| Cash retail (pen) | $1,349 | $1,059 |
| Manufacturer direct-pay | NovoCare ~$499 (pen) | Lilly Direct $349-$499 (vial) |
| Patient assistance (if qualified) | $0 | $0 |
| Compounded alternative | $199-$399 (semaglutide) | $299-$549 (tirzepatide) |
For cash-pay patients, the comparison depends on injection preference (pen vs. vial), clinical fit, and tolerance. Tirzepatide has historically produced larger mean weight loss in head-to-head trials (SURPASS-2 in diabetes, SURMOUNT vs. STEP indirect comparisons). Semaglutide has a longer track record. The "right" molecule for cash-pay choice is a clinical conversation, not just a pricing one.
International Wegovy considerations
Wegovy is approved in many countries. Personal importation from accredited Canadian pharmacies can run $200 to $400 monthly. Risks include seizure, counterfeit, and cold-chain failures. With NovoCare's direct-pay program at $499, the price gap that once made international importation attractive has narrowed substantially.
Annual cost projections across paths
| Path | Approximate monthly cost | Approximate annual cost |
|---|---|---|
| Cash retail Wegovy | $1,349 | $16,188 |
| NovoCare direct-pay | ~$499 | ~$5,988 |
| Novo Nordisk PAP (if approved) | $0 | $0 |
| Compounded semaglutide via 503A | $199-$399 | $2,388-$4,788 |
| International Wegovy from accredited pharmacy | $200-$400 | $2,400-$4,800 |
The decision framework
Step 1: If you qualify for the Novo Nordisk PAP (income at or below 400% of FPL), apply. Approval = $0.
Step 2: While the application is pending, or if you do not qualify, use NovoCare direct-pay at ~$499 for brand Wegovy.
Step 3: If $499 is still out of reach, compounded semaglutide via a reputable 503A pharmacy is the next-cheapest legal path, with the regulatory caveats discussed.
Step 4: Consider whether Zepbound (Lilly Direct vials) is a clinically appropriate alternative; it is the cheapest brand-name path among GLP-1 weight-management options.
Step 5: International importation is a last-resort option with real risks. The savings advantage over NovoCare has shrunk.
What we see on the FormBlends platform
Uninsured patients seeking Wegovy commonly arrive expecting to pay close to $1,349. After clarifying the options:
Roughly 25 percent qualify for the Novo Nordisk PAP and end up at $0.
Roughly 30 percent use NovoCare direct-pay at $499 because they prefer brand and can afford that tier.
Roughly 35 percent choose compounded semaglutide for lower cost.
The remaining 10 percent pivot to Zepbound via Lilly Direct or to alternative agents based on clinical fit.
FAQ
How much is Wegovy without insurance in 2026? Approximately $1,349 per month at U.S. cash retail; approximately $499 through NovoCare direct-pay.
What is NovoCare Pharmacy's cash-pay price for Wegovy? Around $499 per month at launch; pricing has been adjusted since. Verify current rate at the time of order.
Can uninsured patients use the Wegovy savings card? An uninsured tier exists but is typically less favorable than NovoCare direct-pay. Run both numbers.
Is compounded semaglutide cheaper than Wegovy? Yes, typically $199-$399 monthly. It is not FDA-approved and not interchangeable with brand Wegovy.
How do I qualify for the Novo Nordisk Patient Assistance Program for Wegovy? U.S. residency, income at or below 400% of FPL, no Wegovy-covering insurance, and an FDA-approved obesity prescription.
Is Wegovy worth the cash-pay cost? STEP 1 data showed ~14.9% mean weight loss at 68 weeks. Whether the cost is justified depends on individual circumstances, alternatives, and budget.
Where is the cheapest place to buy Wegovy without insurance? Patient assistance ($0) for qualifying patients; NovoCare direct-pay (~$499) for everyone else; compounded semaglutide outside the brand channel.
Can I import Wegovy from Canada or Europe to save money? Personal importation is a gray area. NovoCare's pricing has reduced the savings advantage.
How long does Novo Nordisk PAP take to approve? Three to six weeks typically. Submit complete documentation to avoid delays.
What is the difference between Wegovy and Ozempic at the cash counter? Same active ingredient. Wegovy has obesity on label and runs higher list price. Ozempic has diabetes on label. Cash retail: Wegovy ~$1,349, Ozempic ~$998.
Will Wegovy get cheaper over time? NovoCare direct-pay represents a structural price move. Generic semaglutide is years away. Medicare negotiation could affect Part D pricing in future cycles.
Sources
- Novo Nordisk. Wegovy Wholesale Acquisition Cost and NovoCare direct-pay documentation. NovoCare.com. 2026.
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. 2024.
- U.S. Department of Health and Human Services. Federal Poverty Level Guidelines 2026. ASPE.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021 (STEP 1).
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021 (STEP 4).
- FDA. Personal Importation Policy. Regulatory Procedures Manual.
- Novo Nordisk Patient Assistance Program documentation. 2026.
- Kaiser Family Foundation. Employer Health Benefits Survey 2025. GLP-1 coverage.
- USP. Standards for Compounded Sterile Preparations (USP 797). 2023.
- PharmacyChecker International Drug Price Comparison Database. 2026.
- FDA. Drug Shortages Database. Semaglutide listings 2022-2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and partnered pharmacies. We do not directly manufacture, prescribe, or dispense medication. The treating provider is responsible for clinical decisions following individual evaluation.
Compounded Medication Notice. Compounded semaglutide referenced in this article is prepared by 503A state-licensed compounding pharmacies in response to individual prescriptions. These preparations are not FDA-approved, have not undergone the FDA drug review process, and are not generic equivalents to brand Wegovy.
Results Disclaimer. Pricing data reflects publicly available information as of May 2026. NovoCare direct-pay pricing, savings card terms, and manufacturer programs change over time. Confirm current pricing with NovoCare or the dispensing pharmacy before relying on figures here.
Trademark Notice. Wegovy, Ozempic, and NovoCare are registered trademarks of Novo Nordisk A/S. Zepbound, Mounjaro, and Lilly Direct are registered trademarks of Eli Lilly and Company. Other brands referenced are property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by either manufacturer.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →